Standard Review for Biogen's BG-12 - Analyst Blog NASDAQ Meanwhile, Biogen and partner Abbott ( ABT ) moved their MS candidate, daclizumab, into a two-year phase III study (DECIDE) in July 2010. Daclizumab is being evaluated as a once-monthly or bi-weekly subcutaneous injection for relapsing-remitting MS. |
